These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22610285)

  • 1. [Resistance to extended-spectrum cephalosporins in non-inducible AmpC enterobacteria: evaluation of the new MIC breakpoints].
    Nastro M; Montoto Piazza L; Saposnik E; García S; Barberis C; Vay C; Rodríguez CH; Famiglietti A
    Rev Argent Microbiol; 2012; 44(1):30-5. PubMed ID: 22610285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli.
    Mirelis B; Rivera A; Miró E; Mesa RJ; Navarro F; Coll P
    Enferm Infecc Microbiol Clin; 2006; 24(6):370-2. PubMed ID: 16792938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
    Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
    J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients.
    Giani T; Antonelli A; Caltagirone M; Mauri C; Nicchi J; Arena F; Nucleo E; Bracco S; Pantosti A; ; Luzzaro F; Pagani L; Rossolini GM
    Euro Surveill; 2017 Aug; 22(31):. PubMed ID: 28797330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital.
    Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH
    APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
    Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Tan TY; Ng SY; Teo L; Koh Y; Teok CH
    J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
    Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
    Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
    Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
    J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TEM and CTX-M genes from ciprofloxacin resistant Proteus mirabilis and Escherichia coli isolated on urinary tract infections (UTIs).
    Rajivgandhi G; Maruthupandy M; Manoharan N
    Microb Pathog; 2018 Aug; 121():123-130. PubMed ID: 29778819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence study of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking inducible ampC from Saudi hospitals.
    Abdalhamid B; Albunayan S; Shaikh A; Elhadi N; Aljindan R
    J Med Microbiol; 2017 Sep; 66(9):1286-1290. PubMed ID: 28820112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.
    Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S
    J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
    Jones CH; Tuckman M; Keeney D; Ruzin A; Bradford PA
    Antimicrob Agents Chemother; 2009 Feb; 53(2):465-75. PubMed ID: 19015360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.